So T, Ishii N
Headaches during the first week or two are typical
10.1016/j.imr.2021.100772 62 LiuD.HeH.YinD.QueA.TangL.LiaoZ.et al (2013)
Food & Drug Administration (FDA) FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025) Journal of the American College of Cardiology (JACC) PROGRESSHF trial: safety and tolerability of elamipretide in heart failure patients Neurology (AAN Journals) MMPOWER2 trial: elamipretide in primary mitochondrial myopathy Genetics in Medicine (Nature) TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome Biochimica et Biophysica Acta (BBA) Bioenergetics Cardiolipin remodeling and cristae structure: role in mitochondrial function Journal of Cardiovascular Pharmacology (PMC) SS31 reduces oxidative stress and improves mitochondrial bioenergetics Alzheimers Drug Discovery Foundation Cognitive Vitality Report: SS31 (elamipretide) preclinical and clinical overview Orphanet Journal of Rare Diseases (PMC) Barth syndrome: clinical presentation, diagnosis, and emerging therapies Centers for Disease Control and Prevention (CDC) Vaccine administration: subcutaneous injection technique (angle, site selection, no aspiration) Johns Hopkins Arthritis Center Patient guide: how to give a subcutaneous injection (stepbystep instructions) NCBI Bookshelf (StatPearls) Best practices for injection: aseptic technique, preparation, and administration Pharmacologic Considerations of Subcutaneous Drug Administration (PMC) Site rotation, absorption kinetics, and prevention of lipohypertrophy Related research, protocols, and guides Explore the available research context, protocol variants or comparisons, and practical guides
Capsule-: 1-2 capsules in a day after breakfast and Lunch
Prescription options: Discuss motility agents with your prescriber if OTC options fail
